# A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

> **NCT05941897** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 39 (actual)

## Conditions studied

- Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** Ceralasertib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05941897
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-21
- **Primary completion:** 2024-07-29
- **Final completion:** 2027-01-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941897, "A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05941897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*